Abstract: Most nutraceutical stability programs are designed to satisfy a single objective of a shelf-life date, which limits the data generated to the minimum required to meet that threshold. The result is a body of stability data that cannot reliably detect formulation vulnerabilities, supplier inconsistencies, or degradation trajectories that put a product below label claim within its own shelf life. A better designed program addresses those failure points with structural decisions that generate durable commercial and regulatory value.

1. Limitations of Threshold-Driven Stability Programs

A stability program built only to declare a shelf-life date proves that the product met its acceptance criteria under the conditions tested, with the materials tested. Stability depends on the active, its partner ingredients, the storage and distribution environment, and how consistent the source and processing are. A threshold-driven program doesn’t examine those variables.

Designing to that minimum makes sense when stability sits on the critical path to launch, and the dataset needed for a date-coded claim is well understood, far more favorable than deriving label claim from charge calculation alone, a shortcut built on compressed timelines and assumptions about stability in familiar platforms.

A program that doesn’t include the variables that affect stability generates the risk of below-label commercial product. Finished goods and ingredient formulations can be affected by supplier-to-supplier variation, active-excipient-packaging interaction, and differences in excipient moisture and hygroscopicity. Contemporary nutraceutical formulations raise additional stability considerations: combination actives creating interaction profiles, probiotics and enzymes with their own viability rules, botanical extracts varying by origin and processing, and the practice of formulating finished goods across very different matrices: softgels, gummies, capsules, and drinks. A single-configuration protocol doesn’t adequately predict stability for all variables.

Finished-goods manufacturers increasingly rely on stability data from their ingredient vendors. Ingredient vendors are unlikely to test stability beyond the conditions the individual ingredient is likely to encounter. Using only that data isn’t a replacement for understanding how the ingredient behaves in the planned finished goods matrix, with its co-ingredients and packaging, under the conditions the product will actually see.

FDA inspection data for dietary supplement manufacturers in 2024 recorded 1,578 failures to establish compliant product specifications [9]. Independent testing of 24 SAM-e supplements purchased on Amazon in October 2024, conducted by NOW Health Group via Eurofins, found that 20 of the 24 failed potency testing; 16 contained less than 20% of labeled potency, and six contained no detectable SAM-e at all, including both gummy products in the sample [10]. Potency failures are consistent with stability programs designed to establish a shelf-life date quickly rather than to determine the actual rate of decomposition.

2. Risks Created by Minimum-Scope Programs

A product testing below its label claim within its own shelf life is a real commercial risk, resulting from either of two program failures: missed formulation vulnerabilities outside the tested configuration, or unaccounted variability in environmental conditions or ingredient content across lots and suppliers. The causes are addressable during development: overage not calibrated to real degradation kinetics, a formulation or supplier change unsupported by updated stability data, lot-to-lot ingredient variability never characterized, or real-life conditions having a greater impact than expected.

A shortfall caught internally means reformulation. The same shortfall caught in a retailer audit, a third-party test, or a regulatory inspection can mean reputational damage, delisting, a warning letter, or a fine. Any of those outcomes exceeds the cost of a more rigorous program at development.

Liu et al. (2026) measured vitamin C degradation kinetics in ready-to-drink nutritional supplement beverages at 20°C, 37°C, and 55°C [15]. The kinetics predict shelf life to label-claim retention: 389 days at 20°C, 198 days at 30°C, 42 days at 50°C in aseptically packaged Tetra Pak formulations, showing the large impact of temperature on rate kinetics. A similar product labeled for a 24-month shelf life with stability data generated exclusively at 25°C would have no data characterizing label-claim integrity at 30°C, which is a condition found in normal product distribution.

2.1 Undetected Formulation Vulnerabilities

A program that tests a single configuration, standard storage conditions, and one lot of starting material won’t detect vulnerabilities that manifest under different conditions, elevated humidity or temperature, interaction between actives, or properties of the formulation matrix and packaging material.

Dosage form is a particularly vulnerable stability variable that single-configuration programs miss. Gummy matrices, characterized by high water activity, typically acidic pH, and hygroscopic excipients, sustain chemical degradation reactions throughout shelf life at rates substantially higher than dry solid dosage forms.

Independent testing of multivitamin supplements in 2023 found quality failures in all four gummy products reviewed, compared to a roughly 30% failure rate across all multivitamin formats tested, with failures including potency both below and above label claim [13]. Moisture sorption drives the physicochemical transitions responsible, including solid-state conversion and hydrolytic degradation, with the magnitude of effect dependent on the specific excipient system and storage humidity [11].

2.2 Ingredient Content Variability

Degradation behavior tracks the complete content of the starting material, not just its declared identity. That content varies between suppliers and between lots from the same supplier. A stability profile built on a single lot from one supplier describes that lot and may not carry over to a different supplier, even when the same incoming specification is met. A supplier change made after stability testing is complete, without bracketed data, leaves the label claim unsupported.

Compositional differences are most pronounced for natural extracts and other ingredients that aren’t isolated to a near-pure concentration or fully characterized. The certificate of analysis may confirm a marker compound but gives limited information about the rest of the composition, which in many ingredients makes up the majority of it. Degradation-product profiles and that unaccounted component mix shift even as the underlying material stays nominally constant, varying with harvest season, growing location, and processing differences.

This variability extends to excipients as well. A property as simple as excipient moisture level can move the stability of the whole formulation. Testing three separate lots to measure variability is the common expectation, but if the lots selected don’t represent the variability the product line will actually encounter, the resulting data can be misleading. Lot selection must be deliberate, chosen to capture actual variability, not convenience.

Independent testing of B vitamin complex and individual B vitamin supplements in October 2024 found that 19% of products contained substantially more or less of one or more vitamins than stated on the label [14]. Label-claim equivalence between products doesn’t predict analytical equivalence, as products making identical label claims demonstrated divergent measured potency, a finding consistent with the dependence of degradation rate on starting material composition.

Stability data is only as reliable as the program that generated it. A program designed to reach a threshold produces evidence that the threshold was reached, not evidence that the product will remain within specification under the full range of conditions it will encounter.

3. The Diagnostic Value of a Well-Designed Stability Program

Stability testing designed with intent beyond shelf-life dating functions as a diagnostic tool for the formulation, the packaging system, and the supply chain. The specific value it generates depends on whether the program is designed to test the parameters relevant to each of these dimensions.

A stability program that includes stress testing and intermediate conditions reveals how the active ingredient responds to environmental conditions, whether excipient interactions and variation within them accelerate degradation, and predicts stability within different delivery forms.

Every protocol should establish which environmental drivers the product must be protected against, light, moisture, oxygen, or some combination. A photosensitive curcumin softgel, a probiotic that fails above a moisture threshold, an oxidation-prone omega oil, and anticipated storage in tropical climates each define a different requirement. The aim isn’t to test behind every possible condition, but to characterize the sensitivity well enough to set a protection target, either within the formulation or the packaging, allowing finished-goods producers to confirm their formulation and packaging choice meets that target.

Supplier qualification exists to bound variability between suppliers and between lots from a single supplier. Stability testing is where that variability shows its consequences. Running stability across sources, and across lots from a single supplier, turns qualification into evidence of how the material actually behaves with real-world variability.

Programs also need to measure the correct parameters, specifically the claim-relevant constituent, not just the labeled active. Substantiating a structure/function or health claim requires showing that the specific constituent responsible for the claimed effect is still present, in the studied form and at the studied level, throughout shelf life. When the claim rests on a defined compound or ratio rather than a total (as with ashwagandha’s withanolide glycoside profile rather than total withanolides), a shelf-life assay measured against a total-content specification can pass while the constituent tied to the claim has drifted.

4. Overage: Insurance or a Substitute for Understanding?

Overage (including active ingredient above the label claim at manufacture) is standard practice in nutraceutical formulation. When correctly applied, it’s a calibrated response to measured degradation kinetics, ensuring the label claim is still met at end of shelf life.

The problem is when overage is set by convention: industry norms, supplier recommendations, or reference to prior formulations in a different matrix. An overage set without reference to the degradation profile of the specific formulation, under the specific storage conditions, with the specific starting material, may be systematically too low, leaving the product vulnerable to below-label-claim results, or too high, resulting in unnecessary cost.

A more damaging pattern uses overage to bury a stability problem rather than resolve it. Raising the overage when an ingredient degrades faster than expected allows finished lots to pass, removing the signal that the formulation requires attention while the underlying instability remains. This effect is most pronounced with low-concentration actives, where the same quantifiable loss that’s trivial for a 500 mg ingredient can eliminate label claim for a 50 mcg one.

Gummy dosage forms illustrate the cost of convention-based overage. Because gummy matrices continue to degrade throughout shelf life, manufacturers typically apply overages of 20–50% above label claim at manufacture [12], not derived from that formulation’s degradation data, but set as an empirical buffer against instability that hasn’t been analytically bounded. The result is biphasic potency behavior: product early in shelf life delivers active content substantially above label claim, while product near expiration may fall below it. Independent market testing has confirmed both outcomes in commercially distributed gummy supplement products [12]. The overage redistributes the potency error across the shelf-life timeline without eliminating it.

Calculate overage from measured degradation kinetics for the specific formulation, not from convention. An overage that stability data can’t justify is a liability in both retailer and regulatory contexts.

5. Source Dependency and the Botanical Complexity Layer

Botanical ingredients introduce complexity that synthetic actives don’t present. Crop year, geographic origin, harvest timing, extraction method, plant part used, and standardization approach all influence the composition of the starting material and the rate and pathway of degradation in finished formulation, with direct implications for label claim integrity.

Stability data generated on one supplier’s botanical material doesn’t transfer to another supplier’s material, even where both meet the same incoming specification. Two suppliers may deliver material satisfying the same CoA assay for a labeled marker compound, while differing in specific compound profile, the ratio of active constituents to co-occurring phytochemicals, and extraction history. Any of those differences can produce meaningfully different degradation behavior in a given formulation matrix.

Ashwagandha illustrates this precisely. A peer-reviewed analysis found that products with equivalent total withanolide content can differ substantially in withanolide glycoside profile, and that this compositional difference, not total content, drives bioavailability and pharmacokinetic performance [3]. A stability program tracking total withanolides can show stable assay values while the specific glycoside profile tied to the label claim has shifted. Two suppliers meeting the same total withanolide specification on their CoAs may deliver materials with meaningfully different degradation trajectories in the same formulation.

Matrix dependence is not confined to compositional variation; it extends to environmental sensitivity as well. Degradation behavior established in one matrix can’t be assumed to apply to a different delivery system, even where the nominal active and dose are equivalent.

Curcumin is among the best-characterized examples of matrix-dependent degradation. Kharat et al. (2017) found that pure curcumin degrades rapidly through hydrolysis and oxidation at pH ≥7.0 in aqueous systems, while holding up better under acidic conditions; degradation rate also varied with molecular environment, with oil-in-water emulsions showing substantially different kinetics than buffer solutions at equivalent pH [16]. The same group extended this to emulsion systems the following year, showing degradation rate at identical storage conditions varying with emulsifier type and concentration [17]. Two curcuminoid formulations with equivalent labeled potency but different delivery matrix (an acidic softgel versus a neutral aqueous beverage) will show different first-order degradation rate constants under identical storage conditions. Data from one matrix can’t predict shelf life in the other.

Because of the inherent variability within a botanical, any meaningful change in supplier, including a change to a supplier meeting incoming specification, should be supported by bracketed stability data.

6. Live Cultures: A Distinct Stability Framework

Products containing live cultures, probiotics, spore-forming organisms, enzyme preparations, present stability requirements categorically different from those applicable to conventional chemical actives. The entity being measured is the viability of a biological organism, not the chemical integrity of a molecular structure.

Standard practice for live culture products is real-time testing under the storage condition specified on the label, carried through the full claimed shelf life. Standard stability frameworks, including ICH Q1A-derived approaches, aren’t directly applicable without this adaptation.

6.1 CFU Labeling and the Time-of-Manufacture Convention

Probiotic products are commonly labeled for CFU count at the time of manufacture rather than at end of shelf life, reflecting the difficulty of guaranteeing viable organism counts across the full range of storage and distribution conditions the finished product may encounter. The practical consequence for stability program design is that the program must characterize the rate and extent of viability loss under defined conditions, to determine whether the product delivers a therapeutically relevant CFU count to the consumer at the point of use.

Grey (2025) documented viability losses of 1–3 log CFU/g over 30 days at ambient temperature in unprotected bacterial cultures, with accelerated loss approaching 37°C [8]. The stability profile is organism-specific, formulation-dependent, and not predictable from the chemical degradation kinetics of co-formulated actives. A program that documents CFU count at manufacture without characterizing viability decline gives no evidence for label claim integrity at the point of use.

6.2 Critical Parameters: Water Activity and Temperature

Two physicochemical parameters govern probiotic viability in dry formulations above all others: water activity and temperature. At water activity values at or below 0.25, probiotic viability is consistently preserved under ambient and moderately elevated temperature conditions. Increasing water activity resumes metabolic activity and shifts organisms from dormancy toward active metabolism, accelerating viability loss in the absence of appropriate nutrients and conditions [7].

Temperature acts through two distinct mechanisms: at elevated temperatures, membrane integrity is compromised and lysis occurs at organism-specific thresholds, a physical destruction event distinct from chemical degradation pathways. At intermediate temperatures above ambient, metabolic activation proceeds without adequate nutrient support, accelerating organism death. Water activity must be measured and controlled as a primary stability parameter, not inferred from moisture content alone.

6.3 Incompatibility of Standard Accelerated Conditions

Conventional chemical stability compresses years of ambient degradation into months using accelerated conditions on the assumption that the same reaction runs faster under heat and humidity. That assumption fails for a living organism: instead of producing an equivalent kinetic relationship, it produces irreversible organism death that can’t be extrapolated to long-term ambient performance [7].

Visciglia et al. (2022) tested a multi-strain synbiotic at 40°C/75% RH and found significant CFU reduction within three months, continuing regardless of water activity control [7]. The mechanism, thermal disruption of membrane integrity and irreversible lysis at organism-specific thresholds, is categorically distinct from the chemical degradation kinetics ICH Q1A’s accelerated conditions are built to compress. Applying 40°C accelerated conditions to a live culture generates data on organism destruction under test conditions, not a kinetic surrogate for long-term viability.

Live culture stability programs need a distinct framework. Water activity and organism-specific temperature thresholds are the primary governing parameters. Standard accelerated conditions don’t apply to live culture products, and using them without adaptation will produce misleading viability data.

7. ICH Q1A as a Reference Framework: Application and Adaptation

ICH Q1A(R2) was developed for pharmaceutical applications and isn’t a regulatory requirement for nutraceuticals in the United States. Its underlying structural logic, though, provides a defensible and systematic reference framework that most nutraceutical-specific guidance doesn’t offer. The value lies in its approach to storage conditions, time points, acceptance criteria, and stress testing, elements frequently underspecified or absent in programs designed solely for shelf-life dating.

7.1 Elements of ICH Q1A Applicable to Nutraceuticals

Several elements translate directly to nutraceutical stability program design: long-term and accelerated storage conditions (25°C/60% RH and 40°C/75% RH) give a standardized basis for degradation rate estimation and shelf-life prediction; defined time points (0, 3, 6, 9, 12, 18, 24 months long-term; 0, 3, 6 months accelerated) support statistical extrapolation of shelf life; stress testing provides mechanistic information on degradation pathways that informs formulation and packaging decisions; and defined acceptance criteria tied to specification limits show whether the product meets claim throughout shelf life, not just at one terminal time point.

7.2 Where Nutraceutical Programs Must Diverge

ICH Q1A was designed around a single, well-characterized pharmaceutical formulation with a defined active substance and a fixed route of administration. Nutraceutical applications present structural differences that require deliberate adaptation.

The same botanical or nutritional ingredient may appear across capsule, tablet, softgel, powder, gummy, and beverage formats, each presenting a different stability environment. A program for an ingredient used across multiple formats requires either format-specific programs or a risk-based bracketing approach identifying the worst-case format as the primary test vehicle.

ICH Q1A assumes a purified active of known structure. Nutraceutical ingredients often aren’t, sometimes by design. Regulated as food rather than drugs, many are minimally processed, carrying high lot-to-lot variability and a large fraction of material beyond the named constituent. That surrounding material isn’t inert: it can contribute to the claimed effect, direct evidence it interacts with the functional ingredient and its degradation.

ICH Q1A-aligned programs also use validated, specific assay methods that distinguish the active from its degradants. Many nutraceutical programs use non-specific methods instead, colorimetric assays, total extract content, that can’t tell active compound from degradation products. Adaptation means adopting methods specific to the actual claimed constituent.

Use ICH Q1A as the starting structure for a nutraceutical stability program, not a compliance target. Keep its storage conditions, time points, and stress-testing approach where the product is a single, well-characterized chemical entity. Adapt or replace them for botanical sourcing, live cultures, multi-format delivery, and analytical method specificity before finalizing the protocol.

8. Designing a Program That Generates Insight

A stability program designed to generate diagnostic value beyond a shelf-life date requires deliberate decisions at the program design stage.

8.1 Define Objectives Before Time Points and Test Samples

The first design decision is to state what the program has to demonstrate. Establishing a shelf-life date, supporting a structure/function claim, qualifying a second supplier, and extending a line into a new format each imply a different design. Objectives determine what goes on stability in the first place: which lots, suppliers, formats, and packaging. Those decisions must be settled before storage conditions, time points, and methods, or the program measures the wrong thing precisely.

8.2 Select Storage Conditions That Reflect Distribution Reality

Standard ambient storage conditions don’t represent the full range of conditions a product will encounter in distribution and retail. Temperature excursions during transport, humidity exposure in distribution centers, and light exposure on retail shelves are relevant stress conditions for most nutraceutical products. Accelerated and stress-testing conditions provide the degradation kinetic data needed to assess product adequacy for the intended supply chain, even where not required by any specific guideline.

8.3 Use Methods That Measure the Right Thing

The method decides what the stability data is worth. A non-specific method can’t separate the active from its degradants, total content reads flat while the actual compound declines. Formal validation is less important than knowing that the method measures the specific claimed constituent accurately.

8.4 Build Supplier and Lot Variability Into the Program

Treat variability as something the program measures, not something handled separately. Running stability across suppliers, across lots from the primary supplier, and on the excipients that make up the bulk of the formulation produces the comparative data that both qualifies a source and defends the claim when the supply chain shifts. Qualification and stability are interconnected and should be considered simultaneously.

8.5 Match Testing Parameters to What’s in the Formulation

A single-configuration, purified chemical active can run the ICH Q1A protocol close to as written. A botanical extract, a live culture, or anything without a purified, well-characterized active needs the structure adapted at the divergence points covered in Section 7.2, broader lot and source sampling for botanicals, real-time testing at label storage conditions, and analytical methods chosen for specificity to the claimed constituent.

8.6 Decision Framework for Existing Programs

For organizations evaluating an existing stability program, the following questions identify primary gaps:

9. Conclusion

Stability data is only as useful as the questions the program was designed to answer. A program designed to generate a shelf-life date produces evidence that a threshold was reached under defined conditions. It doesn’t establish that the product holds up to formulation variability, supplier inconsistency, or the range of environmental conditions encountered in distribution and retail. Nor does it provide the evidentiary foundation for regulatory substantiation of a benefit claim, or the comparative supplier data necessary to qualify an alternative source without additional stability work.

The incremental investment required to extend a minimum stability program to one that addresses these dimensions is substantially smaller at the design stage than the cost of remediation following a below-label-claim result, a retailer audit finding, or a regulatory inquiry. Stability program design is a development decision with downstream commercial and regulatory consequences that extend substantially beyond the shelf-life date it generates.

Pathway 2 Product provides stability program design, supplier qualification support, and regulatory substantiation assessment for nutraceutical ingredient and finished goods developers. Inquiries may be directed to info@pathway2product.com.

References

  1. Veatch-Blohm ME, Chicas I, Margolis K, Vanderminden R, Gochie M, Lila K. (2021). Screening for consistency and contamination within and between bottles of 29 herbal supplements. PLoS ONE. PMC8610273.
  2. Osman A, Chittiboyina AG, Avula B, Ali Z, Adams SJ, Khan IA. (2023). Quality Consistency of Herbal Products: Chemical Evaluation. PMID 37392312.
  3. Rathi P, Kim SK. (2025). Randomized, Double-Blind, Crossover Study Comparing the Bioavailability of 4 Ashwagandha (Withania somnifera) Extracts in Healthy Adults Under Fasting Condition. Current Therapeutic Research. PMC12337022.
  4. ICH Q1A(R2). (2003). Stability Testing of New Drug Substances and Products. International Council for Harmonisation.
  5. Upton R, David B, Gafner S, Glasl S. (2019). Botanical ingredient identification and quality assessment: strengths and limitations of analytical techniques. Phytochemistry Reviews. https://doi.org/10.1007/s11101-019-09625-z
  6. Gafner S, et al. (2023). Botanical Ingredient Forensics: Detection of Attempts to Deceive Commonly Used Analytical Methods. Journal of Natural Products. 86(2):460–472. PMC9972475.
  7. Frontiers in Microbiology. (2022). Assessment of shelf-life and metabolic viability of a multi-strain synbiotic using standard and innovative enumeration technologies. PMC9672074.
  8. Grey B. (2025). Probiotic Stability Research Insights to Maintain CFU Count. GreyB Research.
  9. cGMP Consulting Inc. (2025). Top FDA Observations in Dietary Supplement Manufacturing, 2023–2024.
  10. NutraIngredients-USA. (2024). SAM-e dietary supplement tests highlight ongoing quality problems.
  11. Ng LH, Ling JKU, Hadinoto K. (2022). Formulation Strategies to Improve the Stability and Handling of Oral Solid Dosage Forms of Highly Hygroscopic Pharmaceuticals and Nutraceuticals. Pharmaceutics. 14(10):2059. PMC9611293.
  12. Contract Laboratory. (2026). Gummy Vitamins: Solving the Shelf-Life Stability Headache.
  13. ConsumerLab.com. (2023). Multivitamin and Multimineral Supplements Review.
  14. ConsumerLab.com. (2024). B Vitamins & Complexes Review.
  15. Liu CL, Chen YM, Huang ML, Yang CM. (2026). Kinetic and thermodynamic characterization of vitamin C and vitamin B1 degradation in ready-to-drink nutritional supplement beverages. Journal of Food Measurement and Characterization. doi:10.1007/s11694-026-04285-y.
  16. Kharat M, et al. (2017). Physical and Chemical Stability of Curcumin in Aqueous Solutions and Emulsions. Journal of Agricultural and Food Chemistry. 65(8):1525–1532.
  17. Kharat M, Zhang G, McClements DJ. (2018). Stability of curcumin in oil-in-water emulsions. Food Research International. 111:178–186.
William Sommer Pathway 2 Product  |  pathway2product.com  |  July 2026